Open Source Proliferation in Clinical Trial Analytics
Key Research Findings:
Use of SAS in clinical trials is facing an inflection point due to cost pressure and lack of capabilities. Furthermore, the prevalence of open source, and lack of SAS skills in a younger generation of programmer analysts is accelerating this movement.
Open source; particularly R then Python, once seen only as exploratory and operational analysis, is gaining wider acceptance yet self-imposed impediments still exist for regulatory submissions.
The next generation of clinical analysis systems need architecture designs must to break SCE modernization cycles that cause friction
Enterprise pharmaceutical sponsors and CROs face similar challenges with current statistical computing environments and are eager to modernize with cloud-based API solutions.